Development, characterization, and <i>in vitro</i> evaluation of poly(ethylene oxide)-<i>block</i>-poly(ε-caprolactone)-α-tocopheryl succinate micelles as a novel nanocarrier for rapamycin delivery.

ABSTRACT: Rapamycin holds significant therapeutic potential for various diseases; however, its clinical application is limited by several formulation challenges, primarily its extremely low aqueous solubility (2.6 μg/mL). To address this, nanoparticle-based delivery systems have emerged as a promising strategy to enhance solubility and enable sustained drug release. Currently, Fyarro® (Aadi Bioscience, Inc.), an albumin-bound nanoparticle formulation, is the only FDA-approved injectable rapamycin product. In this study, we aimed to develop and evaluate novel poly(ethylene oxide)-block-poly(ε-caprolactone)-α-tocopheryl succinate (PEO-b-PCL-α-TS) micelles and assess their potential as a delivery system for rapamycin. PEO-b-PCL copolymers with varying PCL/PEO ratios were prepared <

SUBMITTER: Binkhathlan Z 

PROVIDER: S-EPMC12166447 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature